Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
Jiang VC, Liu Y, Jordan A, Leeming A, McIntosh J, Huang S, Zhang R, Cai Q, Chen Z, Li Y, Che Y, Nie L, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang M.
Jiang VC, et al. Among authors: martensson l.
J Hematol Oncol. 2022 Apr 11;15(1):42. doi: 10.1186/s13045-022-01257-9.
J Hematol Oncol. 2022.
PMID: 35410313
Free PMC article.